Patients with ADHD experience unstable treatment baselines, adverse medication side effects, and a lack of structured medical guidance while rapidly switching between different psychiatric medications due to rushed clinical appointments and poor provider documentation.
Patients with ADHD experience unstable treatment baselines, adverse medication side effects, and a lack of structured medical guidance while rapidly switching between different psychiatric medications.
Been an awful month / vent
Been an awful month / vent
Individuals actively switching or adjusting stimulant and non-stimulant medications who suffer from inconsistent medical oversight.
Multiple complaints regarding disruptive side effects across Vyvanse, Adderall, and Focalin paired with disorganized, rushed medical supervision and missing provider notes.
Focuses specifically on the chaotic transition and titration phase rather than generic medication reminders, empowering patients to self-advocate with concrete data.
A streamlined patient-side mobile and web app to log daily symptoms, side effects, and dosing schedules during medication titration, generating structured physician-ready summary reports for appointments.
Patients experience intense frustration and trial-and-error costs over months without a baseline; $9/mo is a low barrier to regain control over expensive and disruptive psychiatric care.
“From chaotic medication titration to clear physician-ready baselines in 6 weeks.”
A streamlined patient-side mobile and web app to log daily symptoms, side effects, and dosing schedules during medication titration, generating structured physician-ready summary reports for appointments.
Target online communities like r/ADHD, r/adhdwomen, and specialized patient support forums where titration struggles are frequently discussed.
Users with ADHD experiencing severe side effects or executive dysfunction may struggle to maintain daily logging habits.
Rushed prescribers may ignore or refuse to review patient-generated PDF reports during short appointment windows.
Providing tracking tools for psychiatric drugs requires careful framing to avoid crossing into medical diagnosis or dosing advice.
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoThis opportunity scores well above the median for ideas surfaced by MonetScope, with a validation sub-score of 9/10 against 3 independently sourced evidence signals. A "strong" rating in this band typically means the pain signal is consistent and recurring across multiple discussions, but one of the three pillars (severity, willingness to pay, or competitor weakness) is somewhat softer than top-tier opportunities. Founders evaluating this should focus customer discovery on the softest pillar first — confirming the gap before committing engineering time to a build.
It sits at the intersection of "analytics", "healthcare", "mobile-app", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.
